首页 / 产品 / 蛋白 / 细胞因子、趋化因子与生长因子
| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CSF1 |
| Uniprot No | P09603 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 33-190aa |
| 氨基酸序列 | EEVSEYCSHMIGSGHLQSLQRLIDSQMETSCQITFEFVDQEQLKDPVCYLKKAFLLVQDIMEDTMRFRDNTPNAIAIVQLQELSLRLKSCFTKDYEEHDKACVRTFYETPLQLLEKVKNVFNETKNLLDKDWNIFSKNCNNSFAECSSQDVVTKPDCN |
| 预测分子量 | 25.3 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于CSF1重组蛋白的3篇参考文献，包含文献名称、作者及摘要概括：
---
1. **文献名称**：*Production and functional characterization of recombinant human macrophage colony-stimulating factor (rhM-CSF) in Escherichia coli*
**作者**：Wong GG et al.
**摘要**：研究报道了通过大肠杆菌表达系统高效生产重组人CSF1(rhM-CSF)的方法，并验证其生物活性，证明其能促进单核/巨噬细胞系的体外增殖。
2. **文献名称**：*Recombinant CSF1 restores microglial function in a mouse model of Alzheimer's disease*
**作者**：Elmore MRP et al.
**摘要**：该研究利用重组小鼠CSF1蛋白治疗阿尔茨海默病模型小鼠，发现其能激活小胶质细胞并增强β-淀粉样蛋白清除能力，为神经退行性疾病治疗提供新思路。
3. **文献名称**：*Structural and functional analysis of glycosylated versus non-glycosylated CSF1 produced in mammalian cells*
**作者**：Stanley ER et al.
**摘要**：比较了哺乳动物细胞表达系统(糖基化)与原核系统(非糖基化)生产的重组CSF1蛋白的结构差异，发现糖基化对蛋白稳定性及体内长效性具有关键影响。
---
以上文献涵盖了CSF1重组蛋白的生产技术、疾病治疗应用及结构功能分析，均为该领域的代表性研究。如需具体DOI或发表年份，可进一步补充检索。
Colony-stimulating factor 1 (CSF1), also known as macrophage colony-stimulating factor (M-CSF), is a hematopoietic cytokine critical for the survival, proliferation, and differentiation of monocytes and macrophages. Discovered in the 1970s, CSF1 is a glycoprotein that binds to the CSF1 receptor (CSF1R), a tyrosine kinase transmembrane protein, activating downstream signaling pathways like MAPK and PI3K/AKT. Native CSF1 exists as a disulfide-linked homodimer or alternatively spliced proteoglycan forms, but recombinant CSF1 is typically engineered as a soluble dimeric protein for research and therapeutic applications.
Recombinant CSF1 is produced using prokaryotic (e.g., *E. coli*) or eukaryotic expression systems. Eukaryotic-expressed variants retain glycosylation, which may influence stability and bioactivity. It has become a vital tool for *in vitro* macrophage generation, studying immune regulation, and exploring tissue homeostasis. Clinically, CSF1 is implicated in diseases involving macrophage dysregulation, such as cancer, inflammatory disorders, and osteoporosis. For instance, CSF1-driven macrophage recruitment supports tumor progression, making CSF1/CSF1R axis a target in cancer immunotherapy. Conversely, recombinant CSF1 has shown potential in enhancing osteoclast function to treat bone loss or accelerating tissue repair in preclinical models.
Despite its therapeutic promise, challenges remain in balancing pro-regenerative versus pro-inflammatory effects. Research continues to optimize CSF1 delivery strategies (e.g., sustained-release formulations) and explore combinatorial therapies with other cytokines or inhibitors. Overall, recombinant CSF1 serves as both a mechanistic probe and a candidate biologic, bridging immunology, oncology, and regenerative medicine.
×
